tbuckley/cabot-search huggingface dataset:
Health care reform and the medical education imperative
Authors: J. S. Todd
Journal: JAMA (1992)

As the ability of the US health care system to meet all the demands placed on it is increasingly challenged, there is hardly a group or organization that does not have a proposal or an ideology to solve the problems of health care costs and access. Notably absent, however, is the notion that if we are to change and improve the present health care system, we must consider how physicians are educated. It is in the earliest days of medical school and residency that physicians' values and attitudes toward their profession are most influenced. A health care system as massive as ours cannot be changed without changing how physicians are educated at all levels. Indeed, a Flexner-like study for the 1990s would be useful, not because medical education is bad, but because it needs to be different. Today, nothing can be considered "business as usual." <h3>Challenges to Medical Education</h3> The
Pneumococcal-Vaccine—Induced Thrombocytopenia
Authors: Barry M. Moss
Journal: JAMA (1982)

<h3>To the Editor.—</h3> Pneumococcal vaccine has been used to protect high-risk individuals from pneumococcal infection.<sup>1</sup>Both local and systemic adverse reactions have been described with the administration of this vaccine.<sup>2</sup>Kelton<sup>3</sup>described two patients with immune thrombocytopenia (ITP) who had relapses of their disease after receiving pneumococcal vaccine. This is another case report of the occurrence of thrombocytopenia in a patient with ITP after receiving this vaccine. <h3>Report of a Case.—</h3> A 17-year-old boy had a platelet count of 18,000/μL of two years' duration. A bone marrow examination disclosed increased megakaryocytes, and secondary causes of thrombocytopenia were excluded. A test for platelet-associated IgG was positive. A regimen of 60 mg/day of prednisone was begun. After an initial favorable response to prednisone administration, the platelet count fell to 40,000/μL. A splenectomy was performed five weeks after the initiation of prednisone therapy. On the day of splenectomy, the platelet
Thermal Effect in Skin Carcinogenesis: Reply
Authors: Weiss, Harold S.
Journal: JNCI Journal of the National Cancer Institute (1981)

Journal Article Thermal Effect in Skin Carcinogenesis: Reply Get access Harold S. Weiss Harold S. Weiss Department of Physiology The Ohio State Univeristy, Columbus, Ohio 43210 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 67, Issue 5, November 1981, Pages 994–995, https://doi.org/10.1093/jnci/67.5.994-a Published: 01 November 1981
TO ABOLISH SMALLPOX QUARANTINE.
Journal: JAMA (1907)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Displaced Registrars
Authors: D. P. Gordon, P. Pratt, R. C. Gledhill, W. S. Locke, T. G. Evans, G. Bradshaw, J. B. Wilson, W. Baruch, J. Breckenridge, H. A. Karrach, T. R. Davison, H. A. Barker, J. M. B. Muirhead, D. F. O'Neill, A. R. Webster, D. H. McMillan, M. Rosen, M. B. Taylor, A. M. Emmerson, W. P. Fullerton, D. C. Simpson, D. A. L. Dick, R. M. Dean, D. Mathieson, H. Michaelson
Journal: BMJ (1950)
The Cover
Authors: Laura King
Journal: JAMA (1995)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
In vivo degradation of porous poly(propylene fumarate)/poly(DL-lactic-co-glycolic acid) composite scaffolds
Authors: Elizabeth L. Hedberg, Henriette C. Kroese-Deutman, Charles K. Shih, Roger S. Crowther, Darrell H. Carney, Antonios G. Mikos, John A. Jansen
Journal: Biomaterials (2005)
Leprosy.
Authors: Wm. Havelburg
Journal: JAMA (1896)

New York, June 23, 1896. <h3>To the Editor:</h3> —I inclose a letter just received from Dr. Wm. Havelburg, the Director of the Bacteriologic Laboratory, Hospital dos Lazaros, Rio Janeiro, Brazil, which will be of interest to American dermatologists. Yours truly, Albert S. Ashmead. "Rio de Janeiro, May 26, 1896. <h3>"Dear Dr. Ashmead:</h3> —I take for granted that you are conversant with the German language, in which I can express myself so much more easily. Accept my best thanks for your many different messages, either of a literary or other character, and I beg you will excuse me for not having rendered my thanks to you before, as I have been prevented by very sad private occurrences. "Your different publications have interested me very much. In regard to the modern way of doctors concerning serum-therapy, I am thoroughly skeptical. Perhaps diphtheria has, for some time been your field; in regard to
A randomized phase II study of nivolumab plus ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST).
Authors: Marit Ahrens, Bernard Escudier, John B. A. G. Haanen, Ekaterini Boleti, Marine Gross Goupil, Marc-Oliver Grimm, Sylvie Negrier, Philippe Barthelemy, Gwenaelle Gravis, Philipp Ivanyi, Jens Bedke, Daniel Castellano, Andrej Panic, Begona Mellado, Pablo Maroto-Rey, Sylvie Rottey, Stefanie Zschaebitz, Dorothee Deckbar, Arndt Hartmann, Lothar Bergmann
Journal: Journal of Clinical Oncology (2021)

TPS4597 Background: Non-clear cell renal cell carcinomas (nccRCC) account for approximately 25% of RCC patients (pts.). Data on treatment strategies for this heterogenous group of RCC are still limited, since most clinical trials focus on clear-cell RCC (ccRCC) histology. Recently combination therapies with immune checkpoint inhibitors (IO, avelumab or pembrolizumab) and tyrosinekinaseinhibitors (TKI) (axitinib) have been approved for treatment in RCC in all International Metastatic RCC Database Consortium (IMDC) risk groups. Additionally nivolumab and ipilimumab (IO/IO) has been approved for treatment in intermediate and high risk pts. showing a significant improvement in overall response rate (ORR), progression free (PFS), and overall survival (OS) compared to sunitinib. Moreover retrospective analysis in nccRCC pts. have shown promising results for IO-based therapies as well in these entities. Methods: In this prospective randomized phase-II multicenter European trial adults with advanced or metastatic nccRCC without prior systemic therapy are eligible. Other key inclusion criteria include: available tumor tissue, Karnofsky &gt;70% and measurable disease per RECIST 1.1. All histological diagnoses are reviewed by a central pathologist. The study plans to randomize ̃306 pts. stratified for papillary or non-papillary non-clear cell histology and by the IMDC risk score. Pts. will be randomized 1:1 to either i) nivolumab 3mg/kg intravenously (IV) plus Ipilimumab 1mg/kg IV every 3 weeks for 4 doses followed by nivolumab fixed dose 240mg IV every 2 weeks or fixed dose 480mg IV every 4 weeks or ii) standard of care therapy according to the approved schedule. Treatment will be discontinued in case of unacceptable toxicity or withdrawal of informed consent. Pts may continue treatment beyond progression, if clinical benefit is achieved and treatment is well tolerated. Primary endpoint is the OS rate at 12 months. Secondary endpoints include OS rate at 6 and 18 months, median OS, PFS, ORR and quality of life. The trial is in progress and 214 patients (132 pts with papillary, 76 pts with non-papillary histology) have been enrolled until now. Clinical trial information: NCT03075423.
THE MOVING PHYSICIAN.
Journal: JAMA (1907)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
LETTER FROM LONDON.
Journal: JAMA (1891)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
ISRAEL
Journal: JAMA (1962)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Taking Telemedicine to the Top of the World
Authors: A. A. Skolnick
Journal: JAMA (1998)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
PRE-COLUMBIAN LEPROSY.
Authors: ALBERT S. ASHMEAD
Journal: JAMA (1895)

Dr. Franz Boas, who has given to the study of American races more time and interest perhaps than any other man living, who has just returned from an investigation of the Indian races of British Columbia, tells me that the Tenachca and Nass River Indians, whose diet consists mainly of small fish, smelts and shell fish (this is the diet which has always been supposed by the common people, and by many doctors, to be the predisposing diet of lepers) are not leprous, but exceedingly syphilitic. Locomotor ataxia is almost epidemic among them. Dr. Gowers, of London, and many of our own specialists assert that locomotor ataxia succeeds syphilis, and that without syphilis there is very little locomotor ataxia. This is not my opinion. My experience in Japan, during two years of hard work, made it evident to me that in that region where they have lived in close familiarity
A Text-Book of Materia Medica for Nurses Including Therapeutics and Toxicology.
Journal: JAMA (1930)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Sodium retention and hepatic function after two-thirds hepatectomy in the rat
Authors: T Ohno
Journal: Hepatology (1991)

Recently it was suggested that the onset of sodium retention in experimental cirrhosis in rats is related to a critical threshold of hepatic function, as assessed by the aminopyrine breath test. The aim of this study was to evaluate whether sodium retention occurred after two-thirds hepatectomy in rats and to investigate the relationship between sodium retention and changes in hepatic function associated with liver regeneration in this model. Sodium balance, creatinine clearance, serum sodium and the aminopyrine rate constant of elimination were evaluated daily for 4 days after surgery in partially hepatectomized (n = 6) and shamoperated rats (n = 6). All rats in the partial hepatectomy group exhibited sodium retention (sodium balance >0.7 mmol/day) 24 hr after surgery. This was associated with a 62% reduction of the aminopyrine rate constant of elimination. Spontaneous natriuresis, which occurred between 2 and 4 days after surgery, was associated with an increase in the aminopyrine rate constant of elimination (from 0.73 ± 0.02 × 10−2 min−1 on the last day of sodium retention to 0.95 ± 0.04 × 10−2 min−1 on the first day of natriuresis [p < 0.05]). In contrast, no change in creatinine clearance occurred over the same period. A negative curvilinear association was found between sodium balance and the aminopyrine rate constant of elimination in all animals (r = −0.72, p < 0.001). These observations indicate that natriuresis is related to the recovery of liver function, not to changes in creatinine clearance. In conclusion, the concept of a critical threshold of liver function below which sodium retention occurs has been substantiated in this model of hepatic dysfunction.
Erratum: The draft genome of the grass carp (Ctenopharyngodon idellus) provides insights into its evolution and vegetarian adaptation
Authors: Yaping Wang, Ying Lu, Yong Zhang, Zemin Ning, Yan Li, Qiang Zhao, Hengyun Lu, Rong Huang, Xiaoqin Xia, Qi Feng, Xufang Liang, Kunyan Liu, Lei Zhang, Tingting Lu, Tao Huang, Danlin Fan, Qijun Weng, Chuanrang Zhu, Yiqi Lu, Wenjun Li, Ziruo Wen, Congcong Zhou, Qilin Tian, Xiaojun Kang, Mijuan Shi, Wanting Zhang, Songhun Jang, Fukuan Du, Shan He, Lanjie Liao, Yongming Li, Bin Gui, Huihui He, Zhen Ning, Cheng Yang, Libo He, Lifei Luo, Rui Yang, Qiong Luo, Xiaochun Liu, Shuisheng Li, Wen Huang, Ling Xiao, Haoran Lin, Bin Han, Zuoyan Zhu
Journal: Nature Genetics (2015)
Abstract 3816: Injection of GSK-3β Overexpressing Bone Marrow Derived Mesenchymal Stem Cells Attenuates Cardiac Dysfunction after Myocardial Infarction
Authors: Jaeyeaon Cho, Peiyong Zhai, Shumin Gao, Junichi Sadoshima
Journal: Circulation (2008)

Glycogen synthase kinase 3β (GSK-3β) induces expression of cardiac markers in mesenchymal stem cells (MSCs). We examined whether injection of ex vivo -modified GSK-3β overexpressing MSCs improves cardiac dysfunction after myocardial infarction (MI). Mouse MSCs were transduced with adenovirus harboring LacZ or GSK-3β (LacZ-MSC or GSK-MSC). MI was induced by coronary ligation and thirty μL of saline alone or MSCs (1.5 x 10 5 cells) were injected into the MI border zone just after coronary ligation. In saline injected MI mice, a progressive increase in left ventricular end diastolic dimension (LVEDD) and a progressive decrease in LV ejection fraction (LVEF) and LV fractional shortening (%FS) were observed compared with sham (Table ). LacZ-MSC or GSK-MSC attenuated increases in LVEDD at 2 and 12 weeks. However, LVEF and %FS were significantly greater in GSK-MSC than in LacZ-MSC group at 2 and 12 weeks (Table ). Heart weight/body weight (HW/BW) in GSK-MSC (4.4±0.1) group was significantly smaller than that in LacZ-MSC (5.1±0.2) and saline (5.0±0.2) groups and not significantly different from that in sham group (4.1±0.0), suggesting that cardiac remodeling was attenuated by GSK-MSC. To further confirm the effect of GSK-3β, MSCs acquired from inducible GSK-3β (tet-OFF) mice were injected into the MI mice fed with or without doxycycline (Dox), where expression of GSK-3β transgene was abrogated by Dox treatment in situ . After two weeks of MI, both LVEF (61.5±2.2, 37.4±7.1, p&lt;0.01) and %FS (27.6±1.4, 15.4±3.2, p&lt;0.001) were significantly greater in Dox (−) (n=13) than in Dox (+) mice (n=9). These results suggest that ex vivo introduction of GSK-3β improves the effect of MSC injection, thereby attenuating LV dysfunction after MI. Furthermore, in situ Dox-regulatable expression of GSK-3β also facilitated the therapeutic effect of MSCs injection. Echocardiography on 2 Weeks and 12 Weeks
Chelation therapy for arteriosclerosis
Authors: A. Soffer
Journal: JAMA (1975)

SOME profess that a certain intravenously administered colorless compound is the elixir of youth. Chelation therapy with edetate disodium (EDTA) solution is described in tones of evangelical fervor in a brochure from a medical clinic: Chelation therapy for hardening of the arteries is a special treatment given by licensed medical doctors for the relief of poor circulation that has been caused by hardening of the arteries (arteriosclerosis, atherosclerosis). The results... are often life-saving and sometimes miraculous.... Each two- to four-hour treatment costs between $20 and $100 depending on the clinic. Each patient requires anywhere between 5 and 30 treatments, often closer to 30. More people aren't doing this treatment... [because] the medical profession is very slow to change and the drug industry directs its efforts to encourage those treatments which will be more profitable to the industry. There are several sites in the United States and Canada
Medicine's position is both pivotal and precarious in assisted-suicide debate
Authors: P. Cotton
Journal: JAMA (1995)

PHYSICIAN-ASSISTED suicide may become as contentious an issue as abortion. The escalating battle pits those who say they are protecting a right to life against those who are demanding a right to choose. Opposing camps are virtually identical to those that war over abortion with one notable exception: organized medicine. "They are two different issues," says American Medical Association (AMA) board of trustees secretary Thomas R. Reardon, MD, an internist in Portland, Ore. "Not even experts agree when life begins," so the AMA maintains that abortion is a medical matter best left between patient and physician. Assisted suicide involves "actively participating in the killing of a living, breathing, functioning, cognitive human being who has a terminal illness," says Reardon. "For myself and for the AMA this is not a religious issue, it is an ethical issue. Our purpose as physicians is to heal." The option of assisted suicide would tarnish